Basit öğe kaydını göster

Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.

dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorMorales-Barrera, Rafael
dc.contributor.authorPowles, Thomas
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorLoriot, Yohann
dc.contributor.authorFlechon, Aude
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorGeczi, Lajos
dc.contributor.authorCheng, Susanna Y.
dc.contributor.authorFradet, Yves
dc.contributor.authorOudard, Stephane
dc.contributor.authorGunduz, Seyda
dc.contributor.authorMa, Junshui
dc.contributor.authorRajasagi, Mohini
dc.contributor.authorVajdi, Amir
dc.contributor.authorCristescu, Razvan
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorAlva, Ajjai Shivaram
dc.date.accessioned2022-07-04T14:33:45Z
dc.date.available2022-07-04T14:33:45Z
dc.date.issued2022
dc.identifier.citationMorales-Barrera R., Powles T., Ozguroglu M., Csoszi T., Loriot Y., Flechon A., Matsubara N., Rodriguez-Vida A., Geczi L., Cheng S. Y. , et al., "Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.", JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.6, 2022
dc.identifier.issn0732-183X
dc.identifier.otherav_8048274e-9826-42c4-ae6e-581db926581d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/183478
dc.identifier.urihttps://doi.org/10.1200/jco.2022.40.6_suppl.540
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleAssociation of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume40
dc.identifier.issue6
dc.contributor.firstauthorID3405490


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster